Dateline: Malvern, Pennsylvania (MALVERN, Pa.) | Wed, 11 Aug 2010
freeNewsArticles Story Summary: “MALVERN, Pa. — Reaction Biology Corporation (RBC) announced today that it has been awarded a Phase II SBIR grant from the National Cancer Institute to expand the reach of its Methyltransferase HotSpot drug discovery platform. The $1.2 million, two-year grant will help fund an expansion of RBC’s methyltransferase screens from 14 to 35 or more.”
A R T I C L E:
Reaction Biology Corporation (“RBC”) announced today that it has been awarded a Phase II SBIR grant from the National Cancer Institute to expand the reach of its Methyltransferase HotSpot(SM) drug discovery platform. The $1.2 million, two-year grant will help fund an expansion of RBC’s methyltransferase screens from 14 to 35 or more.
RBC’s HotSpot(SM) technology is an ultra-low volume tritium-based assay platform that provides gold-standard methyltransferase inhibition data.
The technology is offered as a screening service, allowing clients to avoid operational issues related to dealing with radioisotope management, and quickly find productive lead candidates.
RBC Chief Technology Officer Haiching Ma said, “Epigenetic mechanisms are increasingly recognized as fundamental to several cancers and many other diseases. Up until now, there has been no cost-effective way to do large-scale methyltransferase screening and profiling. We hope that RBC’s ability to fill this unmet need will speed the discovery of new drugs in this area.”
Based in Malvern, PA, RBC specializes in providing high quality biochemical enzyme assay data, using ultra-low volumes and proprietary methods. RBC has provided its services to over 190 customers worldwide, including large pharmaceutical, biotech, government, and academic labs.
RBC’s Kinase HotSpot platform is a widely used service for providing high quality low-cost kinase screening data worldwide. The company also provides HDAC, protease, and other screening services, as well as custom assay development and partnerships.
For more information, visit: www.reactionbiology.com .
###
Copyright © 2010 by Reaction Biology Corporation and Send2Press® Newswire, a service of Neotrope® – all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.
• Web Image (72dpi): https://www.send2press.com/mediaboom/10-0811-reactionbio_72dpi.jpg
• Story Title: Reaction Biology Receives NCI Grant Award for Epigenetic Platform
• REFERENCE KEYWORDS/TERMS: drug discovery, Malvern, Pennsylvania, RBC Kinase HotSpot, Drugs and Pharmaceuticals, Pharma, , MALVERN, Pa..
IMPORTANT NOTICE: some content which is considered “old” or “archival” may reference an event which has already occurred; some content possibly considered “advertorial” may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Reaction Biology Corporation); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Wed, 11 Aug 2010 15:54:06 GMT].
USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.